4 months 1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? The Motley Fool
Revenue growth during what should be a disastrous patent cliff is encouraging.
AbbVie (ABBV) · NYSE · Wall Street
Revenue growth during what should be a disastrous patent cliff is encouraging.
AbbVie (ABBV) · NYSE · Wall Street